BeiGene Ltd, a Beijing-headquartered commercial-stage biotech company with a spinoff created in SIP's BioBay in 2015, went public at Hong Kong Exchanges and Clearing Market (HKEX) on Aug 8, becoming the first among its domestic peers to be listed at both NASDAQ in the United States and HKEX in Hong Kong.

BeiGene, founded in 2010, focuses on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for cancer treatment. It came into open transactions at NASDAQ on Feb 3, 2016, with stock price currently maintained above US$ 170/share.

The company raised HK$ 7.1 billion (RMB 6.828 billion) in the debut offering on the Hong Kong stock exchange through the sale of 65.6 million shares at HK$ 108. It was unveiled that 75% of the fund will be used for discovery of new drugs, 15% for business development and product portfolio expansion and 10% for daily operation and enhancement of internal capabilities.